These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 28961280)
21. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Nuttall J; Kashuba A; Wang R; White N; Allen P; Roberts J; Romano J Antimicrob Agents Chemother; 2012 Jan; 56(1):103-9. PubMed ID: 21986823 [TBL] [Abstract][Full Text] [Related]
28. Improvement of Tenofovir vaginal release from hydrophilic matrices through drug granulation with hydrophobic polymers. Notario-Pérez F; Martín-Illana A; Cazorla-Luna R; Ruiz-Caro R; Peña J; Veiga MD Eur J Pharm Sci; 2018 May; 117():204-215. PubMed ID: 29477644 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic modeling of a gel-delivered dapivirine microbicide in humans. Halwes ME; Steinbach-Rankins JM; Frieboes HB Eur J Pharm Sci; 2016 Oct; 93():410-8. PubMed ID: 27559026 [TBL] [Abstract][Full Text] [Related]
30. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. Valley-Omar Z; Sibeko S; Anderson J; Goodier S; Werner L; Arney L; Naranbhai V; Treurnicht F; Abrahams MR; Bandawe G; Swanstrom R; Karim QA; Karim SS; Williamson C J Infect Dis; 2012 Jul; 206(1):35-40. PubMed ID: 22551813 [TBL] [Abstract][Full Text] [Related]
31. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. Succop SM; MacQueen KM; van Loggerenberg F; Majola N; Karim QA; Karim SS AIDS Care; 2014; 26(12):1521-5. PubMed ID: 25285564 [TBL] [Abstract][Full Text] [Related]
32. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Zhang T; Sturgis TF; Youan BB Eur J Pharm Biopharm; 2011 Nov; 79(3):526-36. PubMed ID: 21736940 [TBL] [Abstract][Full Text] [Related]
33. Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial. Hoffman S; Morrow KM; Mantell JE; Rosen RK; Carballo-Diéguez A; Gai F Arch Sex Behav; 2010 Jun; 39(3):748-60. PubMed ID: 19636696 [TBL] [Abstract][Full Text] [Related]
34. Design and validation of a multiplexed low coherence interferometry instrument for in vivo clinical measurement of microbicide gel thickness distribution. Drake TK; Desoto MG; Peters JJ; Henderson MH; Murtha AP; Katz DF; Wax A Biomed Opt Express; 2011 Oct; 2(10):2850-8. PubMed ID: 22025989 [TBL] [Abstract][Full Text] [Related]
36. Using modeling to help understand vaginal microbicide functionality and create better products. Katz DF; Gao Y; Kang M Drug Deliv Transl Res; 2011 Jun; 1(3):256-76. PubMed ID: 22545245 [TBL] [Abstract][Full Text] [Related]
37. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir. Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439 [TBL] [Abstract][Full Text] [Related]
38. Measurement of Vaginal Microbicide Adherence Using Visual Inspection as Compared to Ultra Violet Light Assessment of Returned Empty Gel Applicators. Upfold M; Grobler A; Suleman F; Mansoor LE AIDS Behav; 2017 Feb; 21(2):462-469. PubMed ID: 27357499 [TBL] [Abstract][Full Text] [Related]
39. Depth-resolved multimodal imaging: Wavelength modulated spatially offset Raman spectroscopy with optical coherence tomography. Chen M; Mas J; Forbes LH; Andrews MR; Dholakia K J Biophotonics; 2018 Jan; 11(1):. PubMed ID: 28703472 [TBL] [Abstract][Full Text] [Related]
40. Vaginal Polyelectrolyte Layer-by-Layer Films Based on Chitosan Derivatives and Eudragit Cazorla-Luna R; Martín-Illana A; Notario-Pérez F; Bedoya LM; Tamayo A; Ruiz-Caro R; Rubio J; Veiga MD Mar Drugs; 2020 Jan; 18(1):. PubMed ID: 31936439 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]